Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The wide range of reported mortality rates reflects heterogeneity in comorbidity and severity of pulmonary embolism. Optimizing risk stratification to prognose pulmonary embolism patients appears to be important to improve management, treatment and clinical outcome.
INTRODUCTION
Pulmonary embolism is a frequent condition in the emergency department and remains one of the leading causes of cardiovascular morbidity and mortality with an average of 10-15% death during the first 1-3 months after diagnosis [1, 2] . However, the mortality rate for acute pulmonary embolism ranges from 65% to less than 1%, depending on the clinical presentation [3, 4] . This wide range of mortality rates reported in literature reflects a major heterogeneity in the health status of patients with pulmonary embolism and the severity of the pulmonary embolism itself. Thus, optimizing risk stratification appears to be an imperative to improve management, treatment and clinical outcome. These last years, risk stratification has been intensively studied as a strategy to select treatment intensity with the goal of improving survival and reducing complications. At the same time, several new orally available anticoagulants that can be initiated without need for heparin have or are poised to receive governmental clearance for commercial sale in Europe and the United States. Risk stratification and new drugs may significantly change therapeutic pulmonary embolism management.
RISK STRATIFICATION
Hemodynamic status at the admission time is the most important prognostic factor of short-term mortality [5, 6] . High-risk pulmonary embolism or massive pulmonary embolism is usually defined by the presence of circulatory shock, which is in turn defined by the presence of or sustained hypotension (systolic blood pressure less than 90 mmHg or a drop at least 40 mmHg for at least 15 min) [7 & ,8] . Fewer than 5% of all pulmonary embolism patients have massive pulmonary embolism but the short-term mortality rates are nearly 50% for these patients [3] . On the other side, patients with normotensive status, accounting for 95% of all pulmonary embolism, can be considered nonhigh-risk pulmonary embolism, and the mortality for this group ranges from 1 to 15%. This large range of mortality reflects a wide spectrum of severity, ranging from pulmonary embolism with compensated shock that could deteriorate at any moment, to trivial pulmonary embolism. Accordingly, researchers have subcategorized normotensive pulmonary embolism into two subgroups: low-risk pulmonary embolism, deemed as low risk for early complication as they could be treated as outpatients; and intermediate-risk pulmonary embolism, which can be further stratified into less-severe and more-severe intermediate risk who may benefit from intensive clinical surveillance and stronger treatment.
Tools for risk stratification
Several tools have been studied for risk stratification: clinical features, imaging and biomarkers.
Clinical features
Several clinical criteria and clinical prognostic models have been proposed in the past decade [9] [10] [11] [12] [13] . The most extensively validated is the Pulmonary Embolism Severity Index (PESI), which was derived and validated on more than 16 000 patients at date [11, [14] [15] [16] . This model requires 11 clinical criteria (Table 1) , and stratifies patients into quintiles of severity, ranging from 1.1% in class I to 24.5% in class V. Forty-one percent of patients were classified into classes I and II with a short-term mortality of 2% only, compared to 14% mortality for patients into classes III-V. When used as dichotomized tool, the PESI provides a highly reproducible negative predictive value of 98-100% for mortality [17] . Recently, authors derived and validated a simplified PESI (sPESI) including only six binary criteria [18] . This simpler version appears to perform equally as well as the original PESI [19 & ]. Using data from an international prospective registry (Registro Informatizado de la Enfermedad TromboEmbolica venosa; RIETE) of more than 15 000 patients with venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary embolism], Laporte et al. [1] identified four clinical predictors for fatal pulmonary embolism: age more than 75 years, presence of DVT, immobilization more than 4 days for a neurological disease, and cancer. Indeed, virtually every registry and prospective study that has examined the effect of comorbidities on pulmonary embolism outcome has found active cancer to worsen prognosis of pulmonary embolism [20] . Kline et al. [21] have derived and validated a specific rule (POMPE-C) for patients with active cancer including eight clinical predictors to predict death within 30 days among patients with
KEY POINTS
Hemodynamic status at the admission time is the most important prognostic factor in terms of shortterm mortality.
Optimizing risk stratification of patients with normotensive pulmonary embolism before they develop overt hemodynamic instability is the challenge of modern pulmonary embolism management and treatment strategy.
Several tools for pulmonary embolism risk-stratification were evaluated: clinical features, imaging (echocardiography, computed tomography and leg ultrasonography) and biomarkers (troponins, natriuretic peptides and so on).
New anticoagulants offer new possibilities especially for out-treatment of low-risk patients. Heart failure þ10
Chronic lung disease þ10
Clinical findings Pulse ! 110 min þ20
Systolic blood pressure < 100 mmHg þ30
Respiratory rate ! 30 min þ20
Temperature < 36 8C þ20
Altered mental status þ60
Arterial oxygen saturation < 90% þ20 
Imaging
In hemodynamically stable patients, echocardiographic right ventricular dysfunction (RVD) has been founded to be associated with a short-term mortality of 10 vs. 3% [22] . A recent meta-analysis found an excellent negative predictive value to this criterion (98%; 95% CI 96-99%), nevertheless the negative likelihood ratio (nLR) to predict mortality was unsatisfactory (0.62; 95% CI 0.41-0.92) leading to think that the prognostic value of right ventricular (RV) dilatation remains uncertain in hemodynamically stable patients [23 & ]. Moreover, there is a lack of standardized definition of echocardiographic criteria for RVD and its practical use is limited by lack of availability 24/7 and operator dependence.
As computed tomography (CT) plays a central role in pulmonary embolism diagnosis and can also assess cardiac morphology, it seems attractive to have simultaneously a diagnostic and prognosis tool. However, the value of RV dilatation assessed on CT by axial measuring right-to-left ventricular dimension ratio (RV/LV) remains uncertain because of conflicting data, poorly characterized interobserver variability, and lack of a large prospective study that was designed to measure prognostic accuracy of CT images [22, 2) is superior to other chest CT signs to predict adverse outcomes and death within 30 days. In another study, considerable differences were found in the interobserver reproducibility of chest CT signs of RVD [26] . Nevertheless, volumetric determination of the RVV/LVV ratio is the least user dependent and the most reproducible (correlation coefficient 0.93; P < 0.001).
The observation of a large, centrally located thrombus provides a beguiling opportunity for clinicians to visualize the potential severity of pulmonary embolism. It is not surprising that several authors have found that the more proximal and larger the thrombi on CT scanning, the higher the probability of associated RVD on echocardiography [27] . However, not all studies have found a good relationship between total pulmonary vascular obstruction and right ventricular pressure or biomarker response, and no study has found either the clot size, location or total pulmonary vascular obstruction to be a significant independent predictor of mortality from pulmonary embolism in a model that includes clinical and biomarker predictors [28] [29] [30] [31] [32] .
Studies have shown conflicting data regarding the concomitant presence of DVT on leg ultrasonography at time of pulmonary embolism diagnosis and VTE recurrence or mortality [10, 33, 34] . Girard et al. did not find a significant association between DVT and prognosis [34] or all-cause death [33] . Wicki et al. found that patients with concomitant DVT have a higher risk of recurrence and death. Recently, Jimenez et al. [35] showed a significant increase of all-cause mortality (15.2 vs. 6.4%), pulmonary embolism-related mortality (6.6 vs. 1.5%) and VTE recurrence (7.2 vs. 1.7%) among pulmonary embolism patients with concomitant DVT as compared to patients without.
Biomarkers Elevated brain natriuretic peptide (BNP) or proBNP were found to be associated with higher risk of mortality 16.7 vs. 1.7% [36] . Lega et al. [37] showed that BNP had an area under the receiver operating characteristic (ROC) curve of 0.92 (95% CI 0.88-0.94), negative likelihood ratio (nLR) of 0.04 and positive likelihood ratio (pLR) of 10.7 for diagnosis of RVD. BNP and proBNP were associated with a higher risk of mortality and serious adverse outcome with odds ratio (OR) 6.2 (95% CI 3-12.7) and 6.7 (3.9-11.6), respectively. The definition of a positive natriuretic peptide concentration has differed between studies and was often determined posthoc [23 & ]. Numerous studies have found elevated BNP to be associated with higher risk of death (OR 7.7; 95% CI 2.9-20.2); the ability of BNP to exclude all-cause adverse effects remains a concern (nLR 0.26).
Troponins were used as markers of myocardial ischemia and were found to be associated with higher risk of mortality 17.9 vs. 2.7% among normotensive patients [38] . However, in a recent and large meta-analysis, pooled likelihood ratio (nLR 0.59 and pLR 2.26) were insufficient to significantly change the pretest-to-posttest probabilities [39] . The authors suggested that troponin might be most useful when associated with another prognostic tool (echocardiographic or CT RVD; or clinical model). These hypotheses were tested in recent studies. Moores et al. [40] , combining troponin to PESI, found that PESI had higher predictive power than troponin for selection of low-risk patients and troponin did not improve the prognostic accuracy of the PESI alone, irrespective of the PESI. On the other side, troponin combined with echocardiographic RVD seems moderately performing better than echocardiography alone: positive predictive value (PPV) 15.2 vs. 11.7; PLR 2.7 vs. 1.98 [41] . Recently, Lankeit et al. [42 & ] showed that using a high-sensitivity troponin (hsT) assay may improve risk stratification. At a cutoff of 14 pg/ml, hsT has 100% sensitivity and negative predictive value (NPV), suggesting that a negative hsT test could rule out early adverse event. This hsT assay also improved identification of high-risk patients especially when combined with echocardiographic RVD (OR 11.87; 95% CI 1.42-99.56) [43] .
Other prognostic biomarkers under early phase investigation include the D-dimer, growth differentiation factor-15 and heart-type fatty acid-binding protein, which promise preliminary results [44, 45] .
Combining model
By using multivariate logistic regression in 515 patients, Sanchez et al. [46 & ] constructed a combined model (PREP score). Using five criteria (altered mental status, cardiogenic shock, cancer, BNP and RV/LV ratio), they identified three risk categories for 30 days adverse event (Table 2 ). In internal validation among hemodynamically stable patients (n ¼ 477), the observed rate of adverse events (shock, respiratory failure or death) was 1.8% for low-risk patients (score < 7; 67.7% of the patients), 11.7% for intermediate-risk patients (score 7-17; 30.4%) and 22.2% for high-risk patients (score ! 18; 1.9%). Recently Chan et al. [47] retrospectively compared the PREP score to the PESI among 302 patients [48] and both scores performed comparably for identifying patients at low risk of mortality, with VPN respectively of 100% and 99%.
NEW ANTICOAGULANTS
In addition to classical antithrombotic therapy [unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, thrombolytic agents, and vitamin K antagonist], new anticoagulants that more selectively inhibit active factors II and X have entered into phase III clinical trials seeking approval to be marketed to treat acute pulmonary embolism. Table 3 summarizes the main characteristics of these new molecules.
Dabigatran, an oral direct thrombin inhibitor, was investigated in the RE-COVER study [48] in which 2539 patients with VTE were first treated by parenteral anticoagulation therapy during 9 days and then randomized (double-blind) in two groups: dabigatran 150 mg Â 2 per day vs. warfarin to achieve INR of 2-3. Results obtained for 541 patients with pulmonary embolism were similar to overall population showing noninferiority of dabigatran vs. warfarin. VTE recurrence or pulmonary embolism-related death were 2.4 vs. 2.1% and major bleeding account, respectively for 1.6 vs. 1.9% for dabigatran vs. warfarin, respectively. Moreover acute coronary syndromes and abnormal liverfunction test were similar in both groups.
Rivaroxaban, an oral direct factor Xa inhibitor, was investigated in the EINSTEIN study for DVT [49] , and results for EINSTEIN-PE were recently published. This randomized, open-label noninferiority trial compared rivaroxaban to classical treatment (enoxaparine followed by vitamin K antagonist). Symptomatic recurrence of venous thromboembolism was the primary efficacy outcome. Among 4832 patients included, it was observed in 50 patients (2.1%) in the rivaroxaban group vs. 44 patients in the classical treatment group. Major bleeding occurred in 26 patients (1.1%) vs. 52 patients (2.2%) respectively. The authors concluded that rivaroxaban was noninferior to classical treatment and a potentially improved benefit-risk profile [50 & ]. Apixaban and edoxaban, also oral direct factor Xa inhibitors, are currently under investigation for the VTE treatment (AMPLIFY NCT00643201, HOKUSAI: NCT00986154).
These oral new anticoagulants do not have any appropriate antidote but preliminary results suggest efficacy of prothrombin complex concentrate for reversal of direct factor Xa inhibitors [51] .
Idrabiotaparinux is a subcutaneous, long-action indirect factor Xa inhibitor. The addition of biotin moiety to idraparinux allows rapid reversal of the anticoagulant effect by avidin infusion without changing is pharmacodynamic effects [52] . Idrabiotaparinux was investigated in the CASSIOPAE study [53 & ] in which 3202 patients with acute pulmonary embolism were randomized (double-blind) in two groups after receiving five to 10 days enoxaparine 1 mg/kg twice daily: subcutaneous idrabiotaparinux 3 mg once weekly or warfarin. Incidence of VTE recurrence at day 99 and 190 was 2% for idrabiotaparinux vs. 3% for warfarin. Relevant bleeding occurred in 5% vs. 7%, respectively at day 99 and 7% vs. 8% at day 190. Idrabiotaparinux appears to be an attractive alternative to warfarin for long-term pulmonary embolism treatment.
As of March 2012, none of these drugs have received marketing clearance from the FDA for the treatment of acute pulmonary embolism.
TREATMENT STRATEGY ACCORDING TO RISK STRATIFICATION
Risk stratification has been intensively studied as a strategy to select treatment intensity.
High-risk pulmonary embolism
There is good evidence on superiority of thrombolysis to heparin alone to accelerate lysis of emboli, restore SBP and lead to more rapid resolution of RVD, although its benefit on short or long-term survival is controversial [54, 55] . This may be due to modest size of studies, to lack of distinction between hemodynamically stable and unstable patients, and differences among the treatment performed including or not invasive procedure. In a recent meta-analysis, a subgroup analysis focused on hemodynamically unstable patients found significant reduction in pulmonary embolism recurrence or death with thrombolysis compared with heparin (9.4 vs. 19.0%; OR 0.45, 95% CI 0.22-0.92) [56] . Moreover, recent studies using alteplase only and avoiding as possible invasive procedure show no increase in major bleeding and especially in intracranial haemorrhage [54] . Thus, consensus exists that patients with hypotension or shock (indicating overt right ventricular failure), who do not have high risk of bleeding should undergo prompt recanalization, and thrombolysis is the first-line treatment recommended (grade 1C) [57 & ].
Nonhigh-risk pulmonary embolism
These patients are usually hospitalized for anticoagulant treatment: intravenous UFH, subcutaneous LMWH or fondaparinux followed most of the time by vitamin K antagonist. The challenge of modern pulmonary embolism management is to optimize risk stratification in order to select a severe-intermediate-risk pulmonary embolism group before they develop overt hemodynamic instability, who may benefit from intensive clinical surveillance and escalated treatment (thrombolysis) and, at the opposite, a low-risk group who may be treated as outpatients.
Severe-intermediate-risk
Several tools, including echocardiographic or CT RVD assessment or elevated biomarkers levels have been investigated to identify RVD and/or [58] randomized (double-blind) 58 hemodynamically stable patients with RVD assessed by echocardiography in two groups: tenecteplase (weightadjusted single bolus) vs. placebo. All patients received UFH. The authors found that tenecteplase is associated with a significant reduction of RV:LV ratio at 24 h, but not at 7 days posttreatment. Recurrent VTE occurred in 3.7% with tenecteplase, vs. 6.6% with placebo, and no death occurred with tenecteplase, vs. 3.3% with placebo; major bleeding occurred in 3.3% vs. 6% patients, respectively. However clinical benefit was not the endpoint of this study. Two ongoing randomized controlled trials (RCTs) of tenecteplase, designed to test patient-oriented, clinically relevant endpoints are underway. The PEITHO trial includes normotensive pulmonary embolism patients, having RVD (assessed by echocardiography or CT) and elevated troponin [59 & ]. This prospective international and double-blind randomized trial compares tenecteplase vs. placebo, and the primary efficacy outcome is the composite of death (any-cause) or hemodynamic collapse within 7 days. Safety outcomes include ischemic/hemorrhagic stroke and major bleeding. Enrolment expected is of 1000 patients and in September 2011, 793 patients were included. A smaller RCT being conducted in the United States, tenecteplase or placebo, cardiopulmonary outcomes at three months (TOPCOAT) seeks to measure the rate of symptomatic RVD after normotensive pulmonary embolism (NCT00680628). These studies may help to resolve the controversy surrounding the use of thrombolysis for normotensive patients with RVD. At the present time, insufficient data are present to warrant any recommendation for use of thrombolytic therapy in this category, nevertheless we suggested hospitalization in intensive care unit for closer surveillance.
Low-risk pulmonary embolism PESI was used to select patients for out-treatment in a randomized study of 344 patients with acute pulmonary embolism [60 & ]. Initial treatment consists of subcutaneous enoxaparine 1 mg/kg twice every day and protocol recommended early initiation of vitamin K antagonist for a minimum of 90 days. VTE recurrence occurred in 0.6% in outpatients vs. 0% in in-patients, death for 0.6% in each group and major bleeding occurred in 1.2% in outpatients vs. 0% in inpatients at 30 days. This leads to recommend early discharge in low-risk patients having adequate home circumstances [57 & ]. Patient's preferences should obviously be taken into account.
Clinical relevance and management of isolated subsegmental pulmonary embolism (ISSPE) are very controversial. In a recent review, Stein et al. [61 & ] suggested to withhold treatment in ISSPE providing some criteria that includes good respiratory reserve, no DVT on serial testing, transient or no longer present risk factor, no history of central venous catheterization or atrial fibrillation and patient acceptance to return for serial venous ultrasonography.
In Fig. 1 , we proposed an algorithm management in risk stratification and treatment strategy for patients with acute pulmonary embolism.
CONCLUSION
Acute pulmonary embolism produces a wide range of clinical severity. The hemodynamic status at the admission time is the most important prognostic factor for short-term mortality followed by the patient's comorbid status. Optimizing risk stratification of patients with normotensive pulmonary embolism before they develop overt hemodynamic instability is the challenge of modern pulmonary embolism management and treatment strategy, which has to integrate new anticoagulants arrival.
